• Elise Weir, Paul D Burns, Anne Devenny, David Young, and James Y Paton.
• Department of Respiratory Paediatrics, Royal Hospital for Children, Glasgow, UK.
• Arch. Dis. Child. 2017 May 1; 102 (5): 440-444.

BackgroundWhile exercise testing is increasingly used as a prognostic indicator in cystic fibrosis (CF), it is reported to be underused in UK CF centres, particularly in children. Here, we evaluated the cardiopulmonary exercise testing (CPET) results in children and young people with CF at CF annual review and its possible clinical value.MethodAn observational study comparing CPET results using a cycle ergometer ramp test (peak oxygen uptake (Vo2peak)) and pulmonary function (forced expiratory volume in 1 s (FEV1)) was performed with body mass index (BMI) used as a disease severity marker. Data were identified from clinical case notes and our CF database.ResultsThirty-eight children and young people (mean age 11±2.4, range 7-14 years; 17 males and 21 females) completed at least one CPET with 95% achieving technically satisfactory tests allowing measurement of Vo2peak. Mean Vo2peak was 107 ±17.6% predicted, range 74%-150% predicted, with 8% having a reduced Vo2peak of <85% of predicted. Mean FEV1 z-score was -0.77±1.24, range -4.42 to 2.24. We did not demonstrate a significant correlation between Vo2peak % predicted and FEV1 z-score (r=0.25, p=0.13), or between Vo2peak % predicted and BMI z-score (r=-0.05, p=0.77). Twenty-eight of 38 completed a second CPET the following year with 71% showing a decline in Vo2peak (mean decline of 8% of predicted value, equivalent to 3.8 mL/kg/min).ConclusionCPET is feasible with 95% of children and young people achieving technically satisfactory assessments starting from age 7. In this group with relatively mild CF, mean Vo2peak was normal with no significant correlation between Vo2peak and FEV1 or BMI, as markers of disease severity. The majority demonstrated a normal Vo2peak. However, 71% showed a downward trend on repeat testing 12-18 months later.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

27 keywords...

hide…